Veracyte Showcases Over 15 Abstracts Highlighting Decipher and TrueMRD Genomic Tests
What if genomic tests could revolutionize the way we treat urologic cancers? Veracyte, Inc. a leading cancer diagnostics company, is making significant strides in this direction. The company will present more than 15 abstracts at the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU), which takes place from February 26-28 in San Francisco. These studies span prostate and bladder cancers, featuring real-world data for Decipher Prostate and new insights from phase II clinical trials, including one utilizing the company’s upcoming TrueMRD™ Muscle-Invasive Bladder Cancer (MIBC) test.
The breadth of data at ASCO GU shows how our Veracyte Diagnostics Platform is driving meaningful insight across multiple urologic cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “In bladder cancer, Decipher is increasingly being integrated into studies that aim to help guide treatment decisions. With TrueMRD, our whole-genome sequencing minimal residual disease platform, we are extending the understanding of tumor evolution and treatment resistance, while also providing critical information to ensure the earlier detection of recurrent disease when a cure may still be achievable.
Key Insights at a Glance
- Decipher Prostate: A 22-gene test that helps inform treatment decisions for patients with prostate cancer.
- Decipher Bladder: A 219-gene test that classifies bladder tumors into five molecular subtypes.
- TrueMRD: A whole-genome sequencing minimal residual disease platform for tracking cancer recurrence and evolution.
- ASCO GU Symposium: Features over 15 abstracts highlighting Veracyte’s urology portfolio.
The Challenge of Precision in Urologic Cancer Care
Just as a navigator uses a detailed map to chart a course, Veracyte is using genomic data to guide clinicians in making more precise treatment decisions for urologic cancers. The company’s Decipher and TrueMRD tests are designed to provide critical insights into tumor biology and patient outcomes, addressing the significant challenge of tailoring treatments to individual patient needs. This precision is crucial in an era where one-size-fits-all approaches are increasingly recognized as inadequate. The stakes are high, as more accurate and personalized treatments can lead to better patient outcomes and potentially save lives.
Why the Window for Action Is Closing Fast
Like a race against time, the rapid evolution of cancer biology demands immediate and informed action. Veracyte’s robust data from the 2026 ASCO GU Symposium underscores the urgency of integrating genomic tests into clinical practice. The SURE-02 phase II trial, for example, highlights the importance of molecular subtyping in muscle-invasive bladder cancer, suggesting a biologically informed strategy for the use of anti-TROP2 ADCs. This approach not only enhances the effectiveness of current treatments but also paves the way for the development of new, more targeted therapies. The conference will provide a platform for clinicians and researchers to share these findings and accelerate the adoption of precision-based care.
Veracyte Mobilizes Genomic Insights for Clinical Decision-Making
Veracyte is at the forefront of advancing urologic cancer care through its comprehensive genomic testing platform. The company’s Decipher Prostate and Decipher Bladder tests are already making a significant impact, with the Decipher Prostate test achieving “Level 1B” evidence status and inclusion in the most recent NCCN® Guidelines for prostate cancer. The upcoming TrueMRD MIBC test, set to be available in the first half of 2026, will further enhance the ability to monitor and manage cancer recurrence. Veracyte continues to strengthen the connection between real-world data and clinical outcomes, ensuring that its tests provide actionable insights for clinicians and patients alike.
Future Outlook
Veracyte’s genomic tests are like a lighthouse guiding ships through treacherous waters, providing clear and reliable information to navigate the complexities of urologic cancer care. The company’s commitment to innovation and collaboration is evident in the breadth and depth of the data being presented at the 2026 ASCO GU Symposium. With the upcoming TrueMRD MIBC test and ongoing research, Veracyte is poised to continue driving meaningful advancements in the field.
Conclusion
The 2026 ASCO GU Symposium marks a significant milestone for Veracyte and the broader urologic cancer community. By leveraging genomic insights, the company is empowering clinicians to make more informed and precise treatment decisions, ultimately improving patient outcomes. Join the conversation in the comments below.
About Decipher Prostate
The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis.
The Decipher Prostate test has been validated in many dozens of published studies involving more than 100,000 patients. It is the only gene expression test to achieve “Level 1B” evidence status and inclusion in the risk-stratification table in the most recent NCCN® Guidelines* for prostate cancer.
About Decipher Bladder
The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively.
Source link: https://www.businesswire.com/
